Skip to main content
Fig. 2 | BMC Bioinformatics

Fig. 2

From: Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance

Fig. 2

The drug resistance-related pathway that Protease might travel to resist from one PI to another. The minimum spanning tree or MST (left) shows the shortest path that leads to different PI resistance from a wild type protease (e.g. complex of protease-DRV at the bottom of the MST). Nodes are coloured and scaled the same as shown in Fig. 1 according to seven PIs: Atazanavir (ATV, cyan), Darunavir (DRV, blue), Indinavir (IDV, red), Lopinavir (LPV, yellow), Nefinavir (NFV, magenta), Saquinavir (SQV, green), and Tipranavir (TPV, purple). Edge thickness is weighted based on correlation between nodes. Highlighted on the right are the major (in bold) and minor mutations that could distinguish four close groups of mutant protease complexes (namely group I, II, III, and IV): PI-binding site region (position 30, 32), protease flap region (position 46–54), and other important major mutations (position 76, 82, 84, and 90). Protease-PI complexes containing major mutations are highlighted in bold. The graph was generated using Gephi v0.82 [37]

Back to article page